Genetic Engineering 3

More about the book

The rapid advancements in genetic engineering have garnered attention from venture capitalists, pharmaceutical companies, and politicians, prompting reflections on the field's unexpected growth. Just five years ago, many scientists anticipated applications would emerge later, yet now products like insulin are in clinical testing. This progress coincides with a decline in industrial support and funding for biomedical research in Britain, leading to a concerning brain drain of young talent essential for training future molecular biologists. The contributions in this volume highlight the high standards of current British research.